Patents by Inventor David R. Lieberman

David R. Lieberman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20210154221
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula I and derivatives thereof.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Diequez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF
    Publication number: 20190022115
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • Processes for preparing protease inhibitors of hepatitis C virus
    Patent number: 8637449
    Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
  • PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20120232247
    Abstract: The present invention relates to synthetic processes useful in the preparation of macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus NS3 protease and have application in the treatment of conditions caused by the hepatitis C virus. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
    Type: Application
    Filed: August 26, 2010
    Publication date: September 13, 2012
    Inventors: Zhiguo Jake Song, Yaling Wang, David M. Tellers, Laura M. Artino, David R. Lieberman
  • Process for the preparation of conjugates useful in the treatment of prostate cancer
    Patent number: 6552166
    Abstract: The present invention is directed to the improved synthesis of compounds of formula I: which may be useful in the treatment of prostate cancer. Such compounds are synthesized in the presence of a carboxyl activating agent, an additive and a base for the preparation of a PSA conjugate which comprises an anthracycline antibiotic and an oligopeptide.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: April 22, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Joseph E. Lynch, Michael A. Robbins, Yao-Jun Shi, David R. Lieberman
  • Salt form of a conjugate useful in the treatment of prostate cancer
    Patent number: 6355611
    Abstract: The present invention is directed to the sodium salt of formula 5: which may be useful in the treatment of prostate cancer and benign prostatic hyperplasia. Also described are lyophilized formulations that comprise the sodium salt 5 or the corresponding free acid.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: March 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Shyam B. Karki, Mark Cameron, David R. Lieberman, Joseph E. Lynch, Michael A. Robbins, Yao-Jun Shi, Örn Almarsson, Michael J. Kaufman, Maneesh J. Nerurkar
  • Process for synthesizing carbapenem intermediates
    Patent number: 5908936
    Abstract: A process for synthesizing a compound of formula I: is disclosed wherein R represents halo or C.sub.1-6 alkyl, unsubstituted or substituted with OP, wherein P represents a protecting group.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: June 1, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Guy R. Humphrey, Ross A. Miller, David R. Lieberman